Treatment of Neuropathic Pain in Leprosy
Märksõnad
Abstraktne
Kirjeldus
Despite large efforts to eradicate leprosy, this curable mycobacterial infection still affects 250,000 new individuals annually. Half of the globe's leprosy patients live in Brazil and India. In 2013, 33,033 new leprosy cases diagnosed in Brazil, with an average incidence of 1.05 cases / 10 000 inhabitants. Most new cases occur in economically restricted regions of the world, but because at least 5% of the general population is genetically susceptible to the causative agent, new cases may occur anywhere worldwide. This is especially true in times of high human geographic dislocation. Thus, leprosy should rank among the differential diagnosis list of general practitioners and specialists treating skin and peripheral nerve disorders even in non-endemic areas.
Mycobacterium leprae is an obligatory intracellular bacterium that invades macrophages and Schwann cells. Although myelinating Schwann cells are relatively resistant to invasion, viable M. leprae cause marked myelin destruction and lead to secondary neuronal phenotypic changes, degeneration, and nerve dysfunction.
Leprosy patients have historically been characterized by cutaneous insensibility in body areas of deformity, and the presence of pain in these patients has been neglected for a long time. It has only been recently acknowledged that leprosy can be associated with pain in general and neuropathic pain in particular. Leprosy patients frequently experience neuropathy in wide areas of the body, which may or may not present with pain. When pain exists, it may be acute or chronic, neuropathic or inflammatory. Leprosy has different clinical presentations (according to the host's innate immune response) that range from localized skin lesions and adjacent intra-epidermal nerve fiber injury to widespread neuropathy distributed in large areas of low body-surface temperature. Neuropathic pain in leprosy may affect 11-22% of patients, and up to 56% of those with chronic pain. Importantly, more than 85% of patients with leprosy-related neuropathic pain developed it after the end of the antimicrobial treatment period. This means that the majority of patients who developed neuropathic pain did so after they were formally cured of the disease, and, in many cases, discharged from medical assistance. Therefore, pain in leprosy can also be inserted as part of the "care after cure" program initiative, along with stigma, deformity and incapacity management strategies.
In recent years several easy-to use screening tools have been developed to screen for neuropathic pain in leprosy patients, such as the douleur neuropathique-4 (DN-4) and others. These tools allow for the rapid (usually 20 seconds to administer) and reliable (high sensitivity) assessment of pain in leprosy patients.
Additionally, very few reports have described he effects of treatment used for neuropathic pain in these patients, and no clinical trials have been conducted for this specific condition to date. One could argue that leprosy patients with neuropathic pain should respond to usual drugs such as tricyclic antidepressants and anticonvulsants (and they usually do), but the selection of the appropriate treatment regimen, the proper timing of treatment initiation and the most cost-effective drug is not an obvious task. Also, and very important, the lack of formal evidence-based data attesting the efficacy of tricyclics and anticonvulsants for the treatment of leprosy associated neuropathic pain hampers further a wider availability of these drugs in economically-restricted areas. All these limitations can be overcome if the current scientific interest in pain in leprosy is maintained and the present high-level research in the area continues to grow similarly to the previous decades.
Here we designed the first placebo-controlled, double blinded randomized trial in the use of flexible-dose amitriptyline (tricyclic antidepressant) for the treatment of neuropathic pain related to leprosy. This study is currently approved by our local Ethics Review Board (CAAE: 45393415.9.0000.0068) and has stared the recruitment phase on March 2017.
Kuupäevad
| Viimati kinnitatud: | 10/31/2017 |
| Esmalt esitatud: | 06/13/2017 |
| Hinnanguline registreerumine on esitatud: | 10/22/2017 |
| Esmalt postitatud: | 10/26/2017 |
| Viimane värskendus on esitatud: | 11/03/2017 |
| Viimati värskendus postitatud: | 11/06/2017 |
| Õppe tegelik alguskuupäev: | 02/28/2017 |
| Eeldatav esmane lõpetamise kuupäev: | 02/28/2019 |
| Eeldatav uuringu lõpetamise kuupäev: | 02/28/2019 |
Seisund või haigus
Sekkumine / ravi
Drug: Treatment
Drug: Placebo
Drug: Tramadol
Faas
Käerühmad
| Arm | Sekkumine / ravi |
|---|---|
| Experimental: Treatment Patients on this arm will receive amitriptyline on flexible doses, starting from 25mg (1 capsule) and titrated to 50mg (2 capsules) or 75mg (3 capsules), based on brief pain inventory (BPI) questionnaire, applied weekly for 3 consecutive weeks. All patients will receive tramadol as a supportive drug for the treatment of neuropathic pain, they are instructed to take 50mg every 8 hours, if pain present. | Drug: Treatment Administer amitriptyline on flexible doses variating from 25mg to 75mg, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire. |
| Placebo Comparator: Placebo Patients on this arm will receive placebo on flexible doses, starting from 1 capsule and titrated to 2 capsules or 3 capsules, based on brief pain inventory (BPI) questionnaire, applied weekly for 3 consecutive weeks. All patients will receive tramadol as a supportive drug for the treatment of neuropathic pain, they are instructed to take 50mg every 8 hours, if pain present. | Drug: Placebo Administer amitriptyline on flexible doses variating from 1 to 3 capsules, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire. |
Abikõlblikkuse kriteeriumid
| Õppimiseks sobivad vanused | 18 Years To 18 Years |
| Uuringuks kõlblikud sood | All |
| Võtab vastu tervislikke vabatahtlikke | Jah |
| Kriteeriumid | Inclusion Criteria: - Presence of spontaneous pain of medium intensity in the last 24 hours with a minimum value of 4 in 10 on a numerical scale, with a maximum of 10 points (summed pain questionnaire) - Duration of pain of at least 6 months - Presence of neuropathic pain "pure" or of clearly dominant character (no other pain, or pain associated unimportant) - Pain due to leprosy confirmed by clinical examination and / or appropriate electrophysiological examination - Ability to properly understand the Portuguese language, being able to understand the methodology of the study and questionnaires - Having provided their consent in writing of their participation in the study Exclusion Criteria: - Linked to the disease in study: - Neuropathic pain from other causes that not Hansen's disease (Diabetes, HIV, and after chemotherapy); - Linked to the treatment: - Hypersensitivity to amitriptyline and tramadol; - Ongoing treatment with monoamine oxidase inhibitors (MAOIs); - Cardiac and ophthalmologic disorders that contraindicate the use of amitryptiline; - Pregnant or nursing women, or even women of childbearing age without the use of contraceptives. - General - Other pain with intensity higher then the neuropathic one; - Ant other condition that may interfere with the evaluation of the study; - Patients who have not given or signed the informed consent form; - Incorrectly completion of the self-assessment of pain notebook in the period between inclusion and randomization (at least 4 scores in 7 days); - Patients who can't be followed on a regular basis or that miss the appointments (we will give a 7 day tolerance for each appointment); - Documented abuse of psychoactive drugs or alcohol; - History of past or actual psychosis; - Actual diagnosis of major depression following the DSM-IV criteria; - Language and cognitive deficits that are capable of interfering with the understanding of the study; - Patients not affiliated with a social security scheme (beneficiary or recipient); - Patients who refuses to sign or are unable to understand the informed consent, under guardianship; - Participation in other research protocol involving the use of any medication during the 30 days preceding the inclusion in the project. |
Tulemus
Esmased tulemusnäitajad
1. Reduction in pain intensity of 30% from baseline measured by verbal analog scale (VAS) [63 days (9 weeks)]
Sekundaarsed tulemusmõõdud
1. Neuropathic pain [63 days (9 weeks)]
2. Neuropathic Pain Symptoms [63 days (9 weeks)]
3. Quality of Life [63 days (9 weeks)]
4. Number of participants with treatment-related adverse events [63 days (9 weeks)]
5. Predictive factor of response [63 days (9 weeks)]
6. Use of backup pain medication [63 days (9 weeks)]
